CDR641L

CDR641L is a preclinical non-coding RNA–targeting therapeutic candidate being developed by Cardior Pharmaceuticals for the treatment of hypertrophic cardiomyopathy. It is described as an oligonucleotide-based agent that exerts its effects via interaction with cardiac non-coding RNAs (ncRNAs), aiming to modulate disease-driving RNA networks underlying pathological cardiac hypertrophy and remodeling.[4][7][16] The specific ncRNA target and sequence have not been disclosed publicly, but CDR641L is part of Cardior’s RNA therapeutic platform focused on correcting root-cause molecular signaling in cardiovascular disease through synthetic oligonucleotides.[4][7][10]